Drugs / QLS1304
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06823609 | Mar 2025 → Nov 2026 expected | cancer | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07235176 | Jan 2026 → Nov 2028 expected | Her2-receptor negative breast cancer | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-06-03 | Qilu Pharmaceutical Co., Ltd. | Results 2026 ASCO直击：齐鲁制药6项创新研究亮相，多款新药数据发布 qilu-pharma.com ↗
综上，对于既往多线治疗失败、尤其是既往接受过免疫治疗的晚期黑色素瘤患者，QLF31907展现出潜在的抗肿瘤活性，且安全性可接受。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-06-03 | Qilu Pharmaceutical Co., Ltd. | 2026 ASCO直击：齐鲁制药6项创新研究亮相，多款新药数据发布 qilu-pharma.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QLS1304 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07235176 ↗ |